Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
XERIS BIOPHARMA HOLDINGS, INC.
AI Executive Summary
AI-powered analysis of 8-K filing content
Xeris Biopharma exchanged approximately $23 million in convertible notes for cash and common stock on June 10, 2026, reducing debt while potentially diluting equity. This capital restructuring signals the company's strategic effort to improve its balance sheet and financial flexibility.
Key Takeaways
Xeris exchanged $23 million in principal amount of 8.00% Convertible Senior Notes due 2028 for a combination of cash and common stock
The cash portion equals the full principal amount being exchanged, while stock portion is valued using 21-day volume-weighted average price starting June 11, 2026
2 more takeaways